Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11843MR)

This product GTTS-WQ11843MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11843MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15724MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ8352MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ2643MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ3599MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ13956MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ3340MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ3911MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ14377MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW